Research says UK's Cancer Drugs Fund failed to benefit patients

28 April 2017
cancerbig

A new study has criticized the Cancer Drugs Fund (CDF), a program set up by the UK government to facilitate access to oncology treatments unavailable through the National Health Service (NHS).

The study, published in the Annals of Oncology, was carried out by researchers from the London School of Hygiene & Tropical Medicine and King’s College London.

It found that the CDF was not good value for patients, or society. In addition, researchers say it may have resulted in patients suffering from toxic side effects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical